- Home
- PRQR vs CVRX Comparison
PRQR vs CVRX Comparison
Compare PRQR & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- CVRX
- Stock Information
- Founded
- PRQR 2012
- CVRX 2000
- Country
- PRQR Netherlands
- CVRX United States
- Employees
- PRQR N/A
- CVRX N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PRQR Health Care
- CVRX Health Care
- Exchange
- PRQR Nasdaq
- CVRX Nasdaq
- Market Cap
- PRQR 309.5M
- CVRX 337.5M
- IPO Year
- PRQR 2014
- CVRX 2021
- Fundamental
- Price
- PRQR $3.62
- CVRX $14.85
- Analyst Decision
- PRQR Strong Buy
- CVRX Buy
- Analyst Count
- PRQR 4
- CVRX 7
- Target Price
- PRQR $7.13
- CVRX $15.83
- AVG Volume (30 Days)
- PRQR 635.3K
- CVRX 405.5K
- Earning Date
- PRQR 11-07-2024
- CVRX 10-29-2024
- Dividend Yield
- PRQR N/A
- CVRX N/A
- EPS Growth
- PRQR N/A
- CVRX N/A
- EPS
- PRQR N/A
- CVRX N/A
- Revenue
- PRQR $20,506,357.00
- CVRX $47,255,000.00
- Revenue This Year
- PRQR $298.83
- CVRX $31.78
- Revenue Next Year
- PRQR N/A
- CVRX $26.70
- P/E Ratio
- PRQR N/A
- CVRX N/A
- Revenue Growth
- PRQR 306.68
- CVRX 34.38
- 52 Week Low
- PRQR $1.18
- CVRX $6.40
- 52 Week High
- PRQR $4.62
- CVRX $33.14
- Technical
- Relative Strength Index (RSI)
- PRQR 54.60
- CVRX 65.08
- Support Level
- PRQR $3.57
- CVRX $13.03
- Resistance Level
- PRQR $3.70
- CVRX $15.95
- Average True Range (ATR)
- PRQR 0.22
- CVRX 0.79
- MACD
- PRQR -0.08
- CVRX -0.22
- Stochastic Oscillator
- PRQR 18.06
- CVRX 62.33
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.